

# The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflammatory Response Enhances the Efficacy of PD-L1 Checkpoint Blockade

Cell Reports

22, 2978-2994

DOI: [10.1016/j.celrep.2018.02.053](https://doi.org/10.1016/j.celrep.2018.02.053)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. <i>Translational Lung Cancer Research</i> , 2018, 7, 691-702.	2.8	8
2	Activation of viral defense signaling in cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879310.	3.2	14
3	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , 2018, 175, 984-997.e24.	28.9	892
4	Beyond the Cell Cycle: Enhancing the Immune Surveillance of Tumors Via CDK4/6 Inhibition. <i>Molecular Cancer Research</i> , 2018, 16, 1454-1457.	3.4	35
5	CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. <i>Trends in Cell Biology</i> , 2018, 28, 911-925.	7.9	273
6	Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling. <i>Clinical Cancer Research</i> , 2018, 24, 6028-6039.	7.0	41
7	Intron retention is a source of neoepitopes in cancer. <i>Nature Biotechnology</i> , 2018, 36, 1056-1058.	17.5	212
8	Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 6511-6523.	7.0	62
9	The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 7175-7188.	7.0	90
10	The Tumor Microenvironment in Colorectal Cancer Therapy. <i>Cancers</i> , 2019, 11, 1172.	3.7	52
11	Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment. <i>FEBS Journal</i> , 2019, 286, 3540-3557.	4.7	59
12	Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials. <i>Frontiers in Oncology</i> , 2019, 9, 510.	2.8	49
13	Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity. <i>Cancer Science</i> , 2019, 110, 2690-2699.	3.9	24
14	Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1295-1305.	10.7	87
15	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. <i>Cancers</i> , 2019, 11, 1033.	3.7	160
16	Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. <i>Anticancer Research</i> , 2019, 39, 3419-3422.	1.1	6
17	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 34.	5.2	55
18	Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation. <i>Biochemical Pharmacology</i> , 2019, 170, 113676.	4.4	64

#	ARTICLE	IF	CITATIONS
19	Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 1084.	2.8	60
20	Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126637.	2.2	146
21	Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2220-2232.	4.1	7
22	Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies. <i>Journal of Cancer</i> , 2019, 10, 5504-5517.	2.5	60
23	DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. <i>Nature Communications</i> , 2019, 10, 4278.	12.8	263
24	Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1587-1601.	10.7	80
25	Screening responsive or resistant biomarkers of immune checkpoint inhibitors based on online databases. <i>Frontiers of Medicine</i> , 2019, 13, 24-31.	3.4	4
26	MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 5.	5.2	352
27	Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. <i>Cancer Treatment Reviews</i> , 2019, 74, 21-28.	7.7	31
28	Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy. <i>Trends in Cancer</i> , 2019, 5, 308-324.	7.4	113
29	Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 999.	4.8	47
30	Immunotherapy in breast cancer: Current status and future directions. <i>Advances in Cancer Research</i> , 2019, 143, 295-349.	5.0	69
31	Immunomodulatory Roles of Cell Cycle Regulators. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 23.	3.7	42
32	Genomic correlates of response to immune checkpoint blockade. <i>Nature Medicine</i> , 2019, 25, 389-402.	30.7	346
33	Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models. <i>Cancer Science</i> , 2019, 110, 1420-1430.	3.9	48
34	Immunotherapy and targeted therapy combinations in metastatic breast cancer. <i>Lancet Oncology</i> , The, 2019, 20, e175-e186.	10.7	329
35	Benzimidazoles: From Antiproliferative to Multitargeted Anticancer Agents. , 2019, , .		0
36	Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future. <i>Journal of Cancer</i> , 2019, 10, 6608-6617.	2.5	39

#	ARTICLE	IF	CITATIONS
37	Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck. <i>Current Opinion in Oncology</i> , 2019, 31, 122-130.	2.4	18
38	To Cycle or Fight? CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity. <i>Clinical Cancer Research</i> , 2019, 25, 21-28.	7.0	46
39	Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 535-542.	1.6	2
40	Targeting CDK4/6 pathways and beyond in breast cancer. <i>Breast</i> , 2019, 43, 8-17.	2.2	22
41	Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment. <i>Clinical Cancer Research</i> , 2019, 25, 921-927.	7.0	85
42	Tumour-intrinsic resistance to immune checkpoint blockade. <i>Nature Reviews Immunology</i> , 2020, 20, 25-39.	22.7	856
43	Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2 <sup>-</sup> Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 1-11.	2.4	20
44	Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 437-442.	5.0	11
45	Development and strategies of CDK4/6 inhibitors. <i>Future Medicinal Chemistry</i> , 2020, 12, 127-145.	2.3	7
46	Comparison of the roles of estrogens and androgens in breast cancer and prostate cancer. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 2756-2769.	2.6	11
47	Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2 <sup>-</sup> Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 566-580.	7.0	125
48	Siah2 control of T-regulatory cells limits anti-tumor immunity. <i>Nature Communications</i> , 2020, 11, 99.	12.8	15
49	Tumour associated glycans: A route to boost immunotherapy?. <i>Clinica Chimica Acta</i> , 2020, 502, 167-173.	1.1	24
50	Anticancer innovative therapy: Highlights from the ninth annual meeting. <i>Cytokine and Growth Factor Reviews</i> , 2020, 51, 1-9.	7.2	0
51	Biomarkers for Response to Immune Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2020, 4, 331-351.	4.5	29
52	CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. , 2020, 8, e000847.		45
53	Targeting DNA Repair, Cell Cycle, and Tumor Microenvironment in B Cell Lymphoma. <i>Cells</i> , 2020, 9, 2287.	4.1	9
54	Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric Cancer. <i>Oncologist</i> , 2020, 25, e1864-e1868.	3.7	25

#	ARTICLE	IF	CITATIONS
55	Unraveling the regulatory role of endoplasmic-reticulum-associated degradation in tumor immunity. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2020, 55, 322-353.	5.2	2
56	A patient with melanoma that became sensitized to immunotherapy after treatment with a CDK4/6 inhibitor. <i>Immunotherapy</i> , 2020, 12, 861-867.	2.0	4
57	PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer. <i>Drug Discovery Today</i> , 2020, 25, 1762-1771.	6.4	25
58	Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors. <i>Cancer Immunology Research</i> , 2020, 8, 1114-1121.	3.4	9
59	Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 580251.	3.5	38
60	SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705.		20
61	Opportunities for Antigen Discovery in Metastatic Breast Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 570049.	4.8	1
62	Cell Cycle Regulation Meets Tumor Immunosuppression. <i>Trends in Immunology</i> , 2020, 41, 859-863.	6.8	34
63	Targeting CDK4/6 in mantle cell lymphoma. <i>Annals of Lymphoma</i> , 2020, 4, 1-1.	4.5	13
64	The antiviral immune forces awaken in the cancer wars. <i>PLoS Pathogens</i> , 2020, 16, e1008814.	4.7	7
65	Mitosis in Cancer Cell Increases Immune Resistance via High Expression of HLA-G and PD-L1. <i>Cancers</i> , 2020, 12, 2661.	3.7	10
66	Inducible deletion of CDK4 and CDK6 â€” deciphering CDK4/6 inhibitor effects in the hematopoietic system. <i>Haematologica</i> , 2021, 106, 2624-2632.	3.5	11
67	CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. <i>Theranostics</i> , 2020, 10, 10619-10633.	10.0	57
68	CDK4/6 inhibitors: a novel strategy for tumor radiosensitization. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 188.	8.6	35
69	Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6479.	4.1	71
70	Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy. <i>Pharmaceutics</i> , 2020, 12, 758.	4.5	6
71	Leptomeningeal metastatic hormone receptor positive, HER2 and PD-L1 negative, breast cancer responds after pembrolizumab added to abemaciclib: A case study. <i>Current Problems in Cancer Case Reports</i> , 2020, 2, 100033.	0.1	1
72	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. <i>Cancer Cell</i> , 2020, 38, 803-817.e4.	16.8	262

#	ARTICLE	IF	CITATIONS
73	Targeted Molecular Therapy in Palliative Cancer Management. , 2020, 5, .		1
74	The application and prospect of CDK4/6 inhibitors in malignant solid tumors. Journal of Hematology and Oncology, 2020, 13, 41.	17.0	91
75	Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 115-126.	3.8	16
76	Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies. Cancer, 2020, 126, 3400-3416.	4.1	19
77	Mechanistic Learning for Combinatorial Strategies With Immuno-oncology Drugs: Can Model-Informed Designs Help Investigators?. JCO Precision Oncology, 2020, 4, 486-491.	3.0	9
78	Senescent Cells in Cancer Therapy: Friends or Foes?. Trends in Cancer, 2020, 6, 838-857.	7.4	259
79	Turning Cold into Hot: Firing up the Tumor Microenvironment. Trends in Cancer, 2020, 6, 605-618.	7.4	562
80	Rational Cancer Treatment Combinations: An Urgent Clinical Need. Molecular Cell, 2020, 78, 1002-1018.	9.7	95
81	Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor. Expert Opinion on Drug Safety, 2020, 19, 945-954.	2.4	11
82	Development and validation of an immune-related prognostic signature in lung adenocarcinoma. Cancer Medicine, 2020, 9, 5960-5975.	2.8	79
83	Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib. Breast, 2020, 52, 132-133.	2.2	5
84	Combined CDK4/6 and PD-1 Inhibition in Refractory SMARCA4-Deficient Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. JCO Precision Oncology, 2020, 4, 736-742.	3.0	12
85	CDK4/RB/E2Fs axis as potential therapeutic target of endometrial cancer. Biomedicine and Pharmacotherapy, 2020, 125, 109870.	5.6	8
86	Beyond Tumor Suppression: Senescence in Cancer Stemness and Tumor Dormancy. Cells, 2020, 9, 346.	4.1	63
87	A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib. Pharmacological Research, 2020, 156, 104686.	7.1	61
88	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 307-319.	3.7	310
89	Immunomodulation by anticancer cell cycle inhibitors. Nature Reviews Immunology, 2020, 20, 669-679.	22.7	86
90	Tumor Milieu Controlled by RB Tumor Suppressor. International Journal of Molecular Sciences, 2020, 21, 2450.	4.1	17

#	ARTICLE	IF	CITATIONS
91	Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition. <i>Cancer Cell</i> , 2020, 37, 514-529.	16.8	201
92	Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. <i>Cell</i> , 2020, 181, 424-441.e21.	28.9	216
93	Pan-cancer molecular analysis of the RB tumor suppressor pathway. <i>Communications Biology</i> , 2020, 3, 158.	4.4	50
94	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2856.	4.1	31
95	Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1. <i>Chinese Medical Journal</i> , 2020, 133, 853-862.	2.3	21
96	Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. , 2020, 8, e000441.		28
97	&lt;p&gt;Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2657-2666.	2.0	9
98	Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 988-998.	4.1	13
99	Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer. <i>Gut</i> , 2021, 70, 127-138.	12.1	49
100	Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 351-361.	1.8	10
101	Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188483.	7.4	7
102	Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. <i>Clinical Cancer Research</i> , 2021, 27, 1267-1277.	7.0	21
103	The RUNX1/RUNX1T1 network: translating insights into therapeutic options. <i>Experimental Hematology</i> , 2021, 94, 1-10.	0.4	16
104	CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 93, 102136.	7.7	25
105	CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. <i>Nature Cancer</i> , 2021, 2, 34-48.	13.2	48
106	Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastomaâ€”backbone or add-on in immune-oncology?. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 153-171.	5.9	23
107	Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy. <i>Oncogene</i> , 2021, 40, 885-898.	5.9	10
108	Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. <i>Science</i> , 2021, 371, 602-609.	12.6	784

#	ARTICLE	IF	CITATIONS
109	How selective are clinical CDK4/6 inhibitors?. <i>Medicinal Research Reviews</i> , 2021, 41, 1578-1598.	10.5	15
110	Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature. <i>Translational Oncology</i> , 2021, 14, 100939.	3.7	18
111	Immunomodulation by targeted anticancer agents. <i>Cancer Cell</i> , 2021, 39, 310-345.	16.8	131
112	Stress relief for cancer immunotherapy: implications for the ER stress response in tumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1165-1175.	4.2	9
113	Ribociclib plus fulvestrant in the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 93-106.	2.4	9
114	Autophagy and senescence: Insights from normal and cancer stem cells. <i>Advances in Cancer Research</i> , 2021, 150, 147-208.	5.0	5
115	The immunomodulatory effects of endocrine therapy in breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 19.	8.6	36
116	3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 847-859.	0.9	7
117	Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy. <i>Onc Immunology</i> , 2021, 10, 1916243.	4.6	15
118	Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1555-1567.	3.3	17
119	CDK4/6 inhibitor plus endocrine therapy for hormone receptorâ€positive, HER2â€negative metastatic breast cancer: The new standard of care. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 3-14.	1.1	11
120	Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e6.	3.9	10
121	Turning cold tumors into hot tumors by improving T-cell infiltration. <i>Theranostics</i> , 2021, 11, 5365-5386.	10.0	324
123	Downâ€regulation of RCC1 sensitizes immunotherapy by upâ€regulating PDâ€L1 via p27 <sup>kip1</sup> /CDK4 axis in nonâ€small cell lung cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4136-4147.	3.6	12
124	Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4870-4882.	7.0	49
125	HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer. <i>Cancer Science</i> , 2021, 112, 1603-1613.	3.9	16
126	Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Frontiers in Oncology</i> , 2021, 11, 624742.	2.8	19
127	CDK4/6 and PI3K inhibitors: A new promise for patients with HER2â€positive breast cancer. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13535.	3.4	14



#	ARTICLE	IF	CITATIONS
128	The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy. <i>European Journal of Pharmacology</i> , 2021, 895, 173867.	3.5	21
129	Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial. <i>Oral Oncology</i> , 2021, 114, 105164.	1.5	11
130	Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2608.	4.1	13
131	Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer. , 2021, 9, e002084.		16
132	Cyclin-dependent kinase inhibitors exert distinct effects on patient-derived 2D and 3D glioblastoma cell culture models. <i>Cell Death Discovery</i> , 2021, 7, 54.	4.7	17
133	Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. <i>Cell Reports</i> , 2021, 35, 108944.	6.4	44
134	Addressing resistance to immune checkpoint inhibitor therapy: An urgent unmet need. <i>Future Oncology</i> , 2021, 17, 1401-1439.	2.4	17
135	Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 661737.	4.8	29
136	Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review. <i>Drug Safety</i> , 2021, 44, 725-732.	3.2	40
137	Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications. <i>Frontiers in Oncology</i> , 2021, 11, 648687.	2.8	29
138	Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. <i>Cancer Discovery</i> , 2021, 11, 2564-2581.	9.4	58
139	Turning tumors from cold to inflamed to improve immunotherapy response. <i>Cancer Treatment Reviews</i> , 2021, 101, 102227.	7.7	42
140	CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory. <i>Cancer Discovery</i> , 2021, 11, 2582-2601.	9.4	62
141	The Immunology of Hormone Receptor Positive Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 674192.	4.8	68
142	Genetic variant within CDK6 regulates immune response to palbociclib treatment. <i>Clinical Immunology</i> , 2021, 235, 108777.	3.2	0
143	Molecular determinants of response to PD-L1 blockade across tumor types. <i>Nature Communications</i> , 2021, 12, 3969.	12.8	79
144	T Cell-Intrinsic CDK6 Is Dispensable for Anti-Viral and Anti-Tumor Responses In Vivo. <i>Frontiers in Immunology</i> , 2021, 12, 650977.	4.8	4
145	Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives. <i>Cancers</i> , 2021, 13, 3035.	3.7	12

#	ARTICLE	IF	CITATIONS
146	Integrated Analysis of Cell Cycle-Related and Immunity-Related Biomarker Signatures to Improve the Prognosis Prediction of Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 666826.	2.8	16
147	Targeting cell-cycle machinery in cancer. <i>Cancer Cell</i> , 2021, 39, 759-778.	16.8	207
149	Cell cycle on the crossroad of tumorigenesis and cancer therapy. <i>Trends in Cell Biology</i> , 2022, 32, 30-44.	7.9	130
150	Selective Inhibition of Aurora Kinase A by AK-01/LY3295668 Attenuates MCC Tumor Growth by Inducing MCC Cell Cycle Arrest and Apoptosis. <i>Cancers</i> , 2021, 13, 3708.	3.7	3
151	Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC. <i>Frontiers in Oncology</i> , 2021, 11, 676041.	2.8	17
152	Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells. <i>Biology</i> , 2021, 10, 768.	2.8	1
153	The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1105-1124.	2.4	26
154	Inhibition of Cyclin Dependent Kinase 4/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma. <i>Annals of Thoracic Surgery</i> , 2022, 114, 1842-1852.	1.3	14
155	Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics. <i>Trends in Microbiology</i> , 2021, 29, 836-848.	7.7	29
156	Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing. , 0, , .		10
157	The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 531-548.	4.1	16
158	Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2738-2748.	12.0	12
159	Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor. <i>Cancer Cell</i> , 2021, 39, 1404-1421.e11.	16.8	71
160	Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma. <i>Melanoma Research</i> , 2021, Publish Ahead of Print, 495-503.	1.2	2
161	A review of immune checkpoint blockade in breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 208-225.	2.2	11
162	Cyclin D-CDK4/6 functions in cancer. <i>Advances in Cancer Research</i> , 2020, 148, 147-169.	5.0	109
165	The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis. <i>Journal of Clinical Investigation</i> , 2020, 130, 5765-5781.	8.2	29
166	A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy. , 2020, 3, 252-275.		18

#	ARTICLE	IF	CITATIONS
167	Targeting PD-L1 Protein: Translation, Modification and Transport. <i>Current Protein and Peptide Science</i> , 2018, 20, 82-91.	1.4	20
168	When Molecular-Targeted Agents Meet Immunotherapy: The Opportunities for Soft Tissue Sarcoma. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 69-82.	1.4	2
169	Metabolic regulation of the cancer-immunity cycle. <i>Trends in Immunology</i> , 2021, 42, 975-993.	6.8	28
170	Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma. , 2019, , 1-22.		0
171	Mechanism of resistance to immune checkpoint inhibitors. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019, 2, 178-188.	2.1	3
172	Cyclin-dependent kinase inhibitors: efficacy and safety. <i>Meditinskii Sovet</i> , 2019, , 42-55.	0.5	2
175	Real-World Outcomes of Treating Advanced Breast Cancer Patients With Palbociclib: A Multicenter Retrospective Cohort Study in Japan—The KBCOG-14 Study. <i>Breast Cancer: Basic and Clinical Research</i> , 2020, 14, 117822342098384.	1.1	11
176	Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma. , 2020, , 1087-1108.		0
177	Ferroptosis Characterization in Lung Adenocarcinomas Reveals Prognostic Signature With Immunotherapeutic Implication. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 743724.	3.7	2
178	CDK inhibitors in cancer therapy, an overview of recent development. <i>American Journal of Cancer Research</i> , 2021, 11, 1913-1935.	1.4	20
179	What's New in Molecular Targeted Therapies for Head and Neck Cancer?. <i>Korean Society for Head and Neck Oncology</i> , 2021, 37, 11-17.	0.1	0
180	Homeoprotein SIX1 compromises antitumor immunity through TGF- $\beta$ -mediated regulation of collagens. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2660-2672.	10.5	5
181	Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives. <i>Cancers</i> , 2021, 13, 5999.	3.7	6
183	Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 724424.	2.8	12
184	Infiltrating T lymphocytes in the tumor microenvironment of small cell lung cancer: a state of knowledge review. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 881-895.	2.5	10
185	Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association. <i>Nature Communications</i> , 2022, 13, 42.	12.8	27
186	Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBECCA trial. <i>European Journal of Cancer</i> , 2022, 162, 45-55.	2.8	12
187	Cyclin-Dependent Kinases as Therapeutic Targets. , 2021, , 505-507.		0

#	ARTICLE	IF	CITATIONS
188	Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 812916.	2.8	13
189	Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. <i>Molecular Cancer</i> , 2022, 21, 28.	19.2	393
190	CDK4 and CDK6 kinases: From basic science to cancer therapy. <i>Science</i> , 2022, 375, eabc1495.	12.6	142
191	CDK4/6 inhibitors induce replication stress to cause long-term cell cycle withdrawal. <i>EMBO Journal</i> , 2022, 41, e108599.	7.8	48
192	CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer. <i>Future Oncology</i> , 2022, 18, 1143-1157.	2.4	8
193	Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas. <i>Biomedicines</i> , 2022, 10, 573.	3.2	8
194	Targeting CDK4/6 for Anticancer Therapy. <i>Biomedicines</i> , 2022, 10, 685.	3.2	11
195	Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 440-462.	46.4	58
196	Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2022, 24, 17.	5.0	45
197	Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. <i>Nature Reviews Urology</i> , 2022, 19, 305-320.	3.8	9
198	Targeting CDK4 and CDK6 in cancer. <i>Nature Reviews Cancer</i> , 2022, 22, 356-372.	28.4	125
199	Cytokine-Induced Senescence in the Tumor Microenvironment and Its Effects on Anti-Tumor Immune Responses. <i>Cancers</i> , 2022, 14, 1364.	3.7	13
200	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839.	7.0	12
201	Targeting DNA repair pathway in cancer: Mechanisms and clinical application. <i>MedComm</i> , 2021, 2, 654-691.	7.2	34
202	Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?. <i>Npj Precision Oncology</i> , 2022, 6, 26.	5.4	13
204	Polysialic Acid Self-assembled Nanocomplexes for Neutrophil-Based Immunotherapy to Suppress Lung Metastasis of Breast Cancer. <i>AAPS PharmSciTech</i> , 2022, 23, 109.	3.3	4
207	Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6729-6747.	6.4	7
208	Immune effects of CDK4/6 inhibitors in patients with HR+/HER2 <sup>+</sup> metastatic breast cancer: Relief from immunosuppression is associated with clinical response. <i>EBioMedicine</i> , 2022, 79, 104010.	6.1	22

#	ARTICLE	IF	CITATIONS
209	CDK4/6 inhibitors sensitize gammaherpesvirus-infected tumor cells to T-cell killing by enhancing expression of immune surface molecules. <i>Journal of Translational Medicine</i> , 2022, 20, 217.	4.4	9
210	CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	14
211	Identification and Functional Analysis of the G1 Phase Cyclin Dependent Kinase Gene Hc-CDK6 in Pearl Mussels ( <i>Hyriopsis cumingii</i> ). <i>Frontiers in Marine Science</i> , 2022, 9, .	2.5	0
212	LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	1
213	Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer. <i>Nature Communications</i> , 2022, 13, .	12.8	14
214	Combination Approaches to Target PD-1 Signaling in Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	13
215	CDK4/6 Inhibition With Anti-“PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD“1 Alone. <i>JCO Precision Oncology</i> , 2022, , .	3.0	0
216	CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors. <i>OncolImmunology</i> , 2022, 11, .	4.6	8
217	CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models. <i>Cancers</i> , 2022, 14, 3361.	3.7	6
218	Generation, secretion and degradation of cancer immunotherapy target PD-L1. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	5.4	5
219	Immunotherapy and breast cancer: an overview. <i>Current Opinion in Oncology</i> , 2022, 34, 587-594.	2.4	13
220	Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models. <i>PLoS ONE</i> , 2022, 17, e0268244.	2.5	3
221	Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 933-944.	4.1	0
222	Recent advances in targeting protein kinases and pseudokinases in cancer biology. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	4
223	Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer. <i>Human Antibodies</i> , 2022, , 1-20.	1.5	0
224	How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review. <i>Biomedicines</i> , 2022, 10, 1822.	3.2	11
225	Redirecting the Neo-Substrate Specificity of Cereblon-Targeting PROTACs to Helios. <i>ACS Chemical Biology</i> , 2022, 17, 2404-2410.	3.4	3
227	Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib. <i>Oncologist</i> , 0, , .	3.7	11

#	ARTICLE	IF	CITATIONS
228	The combined prognostic model of copper-dependent to predict the prognosis of pancreatic cancer. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	4
229	CDK4: a master regulator of the cell cycle and its role in cancer. <i>Genes and Cancer</i> , 2022, 13, 21-45.	1.9	18
230	Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2022, 1869, 119346.	4.1	13
231	Out of the cycle: Impact of cell cycle aberrations on cancer metabolism and metastasis. <i>International Journal of Cancer</i> , 2023, 152, 1510-1525.	5.1	7
232	Advanced Acral Melanoma Therapies: Current Status and Future Directions. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1405-1427.	3.0	9
233	The Potential for Selective Cyclin-Dependent Kinase 4/6 Inhibition in the Therapy for Head and Neck Squamous Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2022, 28, 377-380.	2.0	2
234	Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR <sup>+</sup> ) Breast Cancer: Spotlight on Convergent CDK6 Upregulation and Immune Signaling. <i>Current Breast Cancer Reports</i> , 0, .	1.0	0
235	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	33
236	Immunotherapy for liposarcoma: emerging opportunities and challenges. <i>Future Oncology</i> , 2022, 18, 3449-3461.	2.4	5
237	Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. <i>Molecular Cancer</i> , 2022, 21, .	19.2	29
238	Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	6
239	Estrogen-induced immune changes within the normal mammary gland. <i>Scientific Reports</i> , 2022, 12, .	3.3	5
240	Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	8.6	9
241	Abemaciclib in combination with pembrolizumab for HR <sup>+</sup> , HER2 <sup>-</sup> metastatic breast cancer: Phase 1b study. <i>Npj Breast Cancer</i> , 2022, 8, .	5.2	14
242	Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers. <i>Breast Cancer Research</i> , 2022, 24, .	5.0	4
243	Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14534.	4.1	3
244	Emerging Therapies for Breast Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2023, 13, a041333.	6.2	2
245	Associating Immunotherapy and Targeted Therapies: Facts and Hopes. <i>Clinical Cancer Research</i> , 2023, 29, 1183-1193.	7.0	3

#	ARTICLE	IF	CITATIONS
246	Rational combinations of targeted cancer therapies: background, advances and challenges. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 213-234.	46.4	69
247	Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade. <i>Cancers</i> , 2022, 14, 6150.	3.7	3
248	Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition. <i>Molecular Oncology</i> , 0, .	4.6	5
249	Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer. <i>Cellular and Molecular Life Sciences</i> , 2023, 80, .	5.4	3
250	Anti-cancer drug molecules targeting cancer cell cycle and proliferation. <i>Advances in Protein Chemistry and Structural Biology</i> , 2023, , 343-395.	2.3	4
251	Deciphering the Immunomodulatory Role of Cyclin-Dependent Kinase 4/6 Inhibitors in the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2236.	4.1	5
252	CDK regulatorsâ€”Cell cycle progression or apoptosisâ€”Scenarios in normal cells and cancerous cells. <i>Advances in Protein Chemistry and Structural Biology</i> , 2023, , 125-177.	2.3	9
253	Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211461.	3.2	5
254	PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer. <i>Journal of Experimental Medicine</i> , 2023, 220, .	8.5	5
255	The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2023, 29, 1996-2011.	7.0	4
256	Kinase inhibitors: Opportunities for small molecule anticancer immunotherapies. <i>Drug Discovery Today</i> , 2023, 28, 103525.	6.4	1
257	Chimeric Antigen Receptor T-cell Therapy in Cancer: A Critical Review. <i>Current Drug Research Reviews</i> , 2023, 15, 241-261.	1.4	2
258	Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	4
259	Therapeutic Implications of CDKs in Breast Cancer. , 2023, , 233-252.		0
260	CDK Dysregulation in Breast Cancer: A Bioinformatics Analysis. , 2023, , 175-194.		0
261	CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. <i>Nature Communications</i> , 2023, 14, .	12.8	14
262	Inhibition of CDK4/6 regulates AD pathology, neuroinflammation and cognitive function through DYRK1A/STAT3 signaling. <i>Pharmacological Research</i> , 2023, 190, 106725.	7.1	3
263	Systemic therapy for hormone receptorâ€”positive/human epidermal growth factor receptor 2â€”negative early stage and metastatic breast cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 480-515.	329.8	23

#	ARTICLE	IF	CITATIONS
264	CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	3.7	6
265	An Overview of CDK Enzyme Inhibitors in Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2023, 23, 603-619.	1.6	2
266	Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer. <i>Cancers</i> , 2023, 15, 2015.	3.7	3
267	Regulative Roles of Metabolic Plasticity Caused by Mitochondrial Oxidative Phosphorylation and Glycolysis on the Initiation and Progression of Tumorigenesis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7076.	4.1	3
268	Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma. <i>Genome Medicine</i> , 2023, 15, .	8.2	5
269	CDK4/6 and autophagy inhibitors synergize to suppress the growth of human head and neck squamous cell carcinomas. <i>Molecular Carcinogenesis</i> , 2023, 62, 1201-1212.	2.7	2
270	Tackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints. <i>Cancers</i> , 2023, 15, 2774.	3.7	3
271	The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	3.7	1
272	CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer. <i>Oncogenesis</i> , 2023, 12, .	4.9	4
273	Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses. , 2023, 11, e006019.		1
275	Regulation of PD-L1 Trafficking from Synthesis to Degradation. <i>Cancer Immunology Research</i> , 0, , OF1-OF9.	3.4	1
276	The prognostic significance of <sc>CDK6</sc> expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition. <i>Scandinavian Journal of Immunology</i> , 0, , .	2.7	0
277	Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
278	Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors. <i>Oncimmunology</i> , 2023, 12, .	4.6	0
279	Immunomodulatory effects of CDK4/6 inhibitors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188912.	7.4	3
280	Breast Cancer Immunity: It is TIME for the Next Chapter. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2024, 14, a041324.	6.2	1
281	Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9571.	4.1	4
283	Enhancing the anticancer immune response with the assistance of drug repurposing and delivery systems. <i>Clinical and Translational Medicine</i> , 2023, 13, .	4.0	0



#	ARTICLE	IF	CITATIONS
284	CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression. <i>Clinical Cancer Research</i> , 2023, 29, 3484-3497.	7.0	3
285	Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study. <i>European Journal of Medical Research</i> , 2023, 28, .	2.2	3
287	Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer. <i>Cell Reports Medicine</i> , 2023, 4, 101120.	6.5	1
288	Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force "Dermatology for Cancer Patients" International Study. <i>Cancers</i> , 2023, 15, 3658.	3.7	3
290	T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2023, 24, 11673.	4.1	1
291	The Therapeutic Potential of CDK4/6 Inhibitors, Novel Cancer Drugs, in Kidney Diseases. <i>International Journal of Molecular Sciences</i> , 2023, 24, 13558.	4.1	0
292	The Role and Therapeutic Targeting of CCR5 in Breast Cancer. <i>Cells</i> , 2023, 12, 2237.	4.1	2
293	Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)., 2023, 11, e007126.		3
294	DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune responses through cGAS-STING pathway. <i>Communications Biology</i> , 2023, 6, .	4.4	1
295	The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer. <i>Cancers</i> , 2023, 15, 4835.	3.7	1
296	CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	0
297	Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	5
298	CDK4/6i enhances the antitumor effect of PD1 antibody by promoting TLS formation in ovarian cancer. <i>Heliyon</i> , 2023, 9, e19760.	3.2	1
299	Harnessing tumor immunity with cytotoxics: T cells monitoring in mice bearing lung tumors treated with anti-VEGF and pemetrexed-cisplatin doublet. <i>British Journal of Cancer</i> , 2023, 129, 1373-1382.	6.4	4
300	CDK4/6 Inhibition Sensitizes Intracranial Tumors to PD-1 Blockade in Preclinical Models of Brain Metastasis. <i>Clinical Cancer Research</i> , 0, , OF1-OF16.	7.0	2
301	MZF1 promotes tumour progression and resistance to anti-PD-L1 antibody treatment in hepatocellular carcinoma. <i>JHEP Reports</i> , 2024, 6, 100939.	4.9	0
302	Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
303	Molecular classification of human papilloma virus-negative head and neck squamous cell carcinomas: Cell cycle-based classifier and prognostic signature. <i>PLoS ONE</i> , 2023, 18, e0286414.	2.5	0

#	ARTICLE	IF	CITATIONS
304	Oncogenic PIK3CA recruits myeloid-derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5-lipoxygenase-dependent arachidonic acid pathway. <i>Clinical and Translational Medicine</i> , 2023, 13, .	4.0	0
305	The Dance Between Tumor Molecular Biology and Antitumor Immune Response. <i>Clinical Cancer Research</i> , 0, , OF1-OF3.	7.0	0
306	The CDK4/6 inhibitor revolution â€” a game-changing era for breast cancer treatment. <i>Nature Reviews Clinical Oncology</i> , 2024, 21, 89-105.	27.6	4
307	Beyond cell cycle regulation: the pleiotropic function of CDK4 in cancer. <i>Seminars in Cancer Biology</i> , 2023, , .	9.6	1
308	Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, .	3.2	0
309	Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. <i>Oncogene</i> , 2024, 43, 729-743.	5.9	0
310	Seize the engine: Emerging cell cycle targets in breast cancer. <i>Clinical and Translational Medicine</i> , 2024, 14, .	4.0	0
311	Effect of CDK4/6 Inhibitors on Tumor Immune Microenvironment. <i>Immunological Investigations</i> , 2024, 53, 437-449.	2.0	0
312	CDK4/6 inhibitors in lung cancer: current practice and future directions. <i>European Respiratory Review</i> , 2024, 33, 230145.	7.1	0
313	The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments. <i>Trends in Cancer</i> , 2024, , .	7.4	0
314	PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	0
315	Overcoming immuno-resistance by rescheduling anti-VEGF/cytotoxics/anti-PD-1 combination in lung cancer model. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 0, , .	2.1	0